The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis

Journal of the Canadian Urological Association

Volumn 7, Issue 5-6, 2013, Pages

  Chua, Michael E ^a   Sio, Maria Christina D ^a   Sorongon, Mishell C ^b   Morales Jr , Marcelino L ^a  

^a ST LUKE S MEDICAL CENTER   (Philippines)

^b International Institute for Neurosciences   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877834812     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.1056     Document Type: Review

References (57)

1. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. http://dx.doi.org/10.1038/nrc2090.
2. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152-60. http://dx.doi.org/10.1200/JCO.2005.03.1492.
3. Chan JM, Stampfer MJ, Ma J, et al. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr 2001;74:549-54.
4. Chan JM, Weinberg V, Magbanua MJ, et al. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control 2011;22:141-50. http://dx.doi.org/10.1007/s10552-010-9684-5.
5. Larsson SC, Kumlin M, Ingelman-Sundberg M, et al. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79:935-45.
6. Carayol M, Grosclaude P, Delpierre C. Prospective studies of dietary alpha-linolenic acid intake and prostate cancer risk: a meta-analysis. Cancer Causes Control 2010;21:347-55. http://dx.doi.org/10.1007/s10552-009-9465-1.
7. Ma RW-L, Chapman K. A systematic review of the effect of diet in prostate cancer prevention and treatment. J Hum Nutr Diet 2009;22:187-99. http://dx.doi.org/10.1111/j.1365-277X.2009.00946.x
8. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk. JAMA 2006;295:403-15. http://dx.doi.org/10.1001/jama.295.4.403.
9. Chua ME, Dy JS. Relationship of Dietary Intake of Omega-3 and Omega-6 Fatty Acids with Risk of Prostate Cancer Development. Philippine Journal of Urology. In Press; 2011.
10. Kohlmeier L. Future of dietary exposure assessment. Am J Clin Nutr 1995;61:S702-9.
11. Byers T, Gieseker K. Issues in the design and interpretation of studies of fatty acids and cancer in humans. Am J Clin Nutr 1997;66:S1541-7.
12. Andersen LF, Solvoll K, Drevon CA. Very-long-chain n_3 fatty acids as biomarkers for intake of fish and n_3 fatty acid concentrates. Am J Clin Nutr 1996;64:305-11.
13. Wolk A, Furuheim M, Vessby B. Fatty acid composition of adipose tissue and serum lipids are valid biological markers of dairy fat intake in men. J Nutr 2001;131:828-33.
14. Zock PL, Mensink RP, Harryvan J, et al. Fatty acids in serum cholesteryl esters as quantitative biomarkers of dietary intake in humans. Am J Epidemiol 1997;145:1114-22. http://dx.doi.org/10.1093/oxfordjournals.aje.a009074.
15. Arab L, Akbar J. Biomarkers and the measurement of fatty acids. Public Helath Nutr 2002;5:865-71. http://dx.doi.org/10.1079/PHN2002391.
16. Baylin A, Kim MK, Donovan-Palmer A, et al. Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma. Am J Epidemiol 2005;162:373-81. http://dx.doi.org/10.1093/aje/kwi213.
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items nfor systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
18. Letts L, Wilkins S, Law M, et al. Guidelines for Critical Review Form: Qualitative Studies (Version 2.0). 2007. http://www.srs-mcmaster.ca/Portals/20/pdf/ebp/qualguidelines_version2.0.pdf. Accessed April 25, 2013.
19. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Accessed April 25, 2013.
20. Greenland S. Quantitative methods in review of epidemiologic literature. Epidemiol Rev 1986;9:1-30.
21. Hunter JE, Schmidt FL. Fixed effect vs. random effects meta-analysis models: implications for cumulative research knowledge. Int J Selection Assess 2000;8:275-92. http://dx.doi.org/10.1111/1468-2389.00156.
22. Borenstein M, Hedges L, Higgins J, et al. Comprehensive Meta Analysis Version 2, Biostat, Englewood, NJ; 2005.
23. Review manager (Revman) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Center, Cochrane Collaboration, 2011.
24. Egger M, Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. http://dx.doi.org/10.1136/bmj.315.7109.629.
25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101. http://dx.doi.org/10.2307/2533446.
26. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63. http://dx.doi.org/10.1111/j.0006-341X.2000.00455.x
27. Godley PA, Campbell MK, Gallagher P, et al. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 1996;5:889-95.
28. Newcomer LM, King IB, Wicklund KG, et al. The association of fatty acids with prostate cancer risk. Prostate 2001;47:262-8. http://dx.doi.org/10.1002/pros.1070.
29. Ukoli FA, Akumabor PN, Oguike TC, et al. The association of plasma fatty acids with prostate cancer risk in Nigerians. Ethn Dis 2009;19:454-61.
30. Shannon A, O'Malley J, Mori M, et al. Erythrocyte fatty acids and prostate cancer risk: A comparison of methods. Prostaglandins Leukot Essent Fatty Acids 2010;83:161-9. http://dx.doi.org/10.1016/j. plefa.2010.06.003.
31. Ukoli FA, Fowke JH, Akumabor P, et al. The association of plasma fatty acids with prostate cancer risk in African Americans and Africans. J Health Care Poor Underserved 2010;21(1 Suppl):127-47. http://dx.doi.org/10.1353/hpu.0.0242.
32. Norrish AE, Skeaff CM, Arribas GLB, et al. Prostate cancer risk and consumption of fish oils: A dietary biomarker-based case-control study. Br J Cancer 1999;81:1238-42. http://dx.doi.org/10.1038/sj.bjc.6690835.
33. Harvei S, Bjerve KS, Tretli S, et al. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 1997;71:545-51. http://dx.doi.org/10.1002/(SICI)1097-0215(19970516)71:4545::AID-IJC73.0.CO;2-U
34. Mannisto S, Pietinen P, Virtanen MJ, et al. Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. Cancer Epidemiol Biomarkers Prev 2003;12:1422-8.
35. Chavarro JE, Stampfer MJ, Li H, et al. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:1364-70. http://dx.doi.org/10.1158/1055-9965.EPI-06-1033.
36. Crowe FL, Allen NE, Appleby PN, et al. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European prospective investigation into cancer and nutrition. Am J Clin Nutr 2008;88:1353-63.
37. Park SY, Wilken LR, Henning SM, et al. Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes Control 2009;20:211-23. http://dx.doi.org/10.1007/s10552-008-9236-4.
38. Brasky TM, Till C, White E, et al. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2011;173:1429-39. http://dx.doi.org/10.1093/aje/kwr027.
39. Meyer BJ, Lane AE, Mann NJ. Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects. Lipids 2009;44:827-35. http://dx.doi.org/10.1007/s11745-009-3333-3.
40. Wang Y, Botolin D, Christian B, et al. Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases. J Lipid Res 2005;46:706-15. http://dx.doi.org/10.1194/jlr.M400335-JLR200.
41. Kaur G, Begg DP, Barr B, et al. Short-term docosapentaenoic acid (22:5n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in rats. Br J Nutr 2009;103:32-7. http://dx.doi.org/10.1017/S0007114509991334.
42. Holub BJ, Swidinsky P, Park E. Oral Docosapentaenoic Acid (22:5n-3) Is Differentially Incorporated into Phospholipid Pools and Differentially Metabolized to Eicosapentaenoic Acid in Tissues from Young Rats. Lipids 2011;46:399-407. http://dx.doi.org/10.1007/s11745-011-3535-3.
43. Henderson RA, Jensen RG, Lammi-Keefe CJ, et al. Effect of fish oil on the fatty acid composition of human milk and maternal and infant erythrocytes. Lipids 1992;27:863-9. http://dx.doi.org/10.1007/BF02535865.
44. Kishida E, Tajiri M, Masuzawa Y. Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factor. Biochim Biophys Acta 2006;1761:454-62. http://dx.doi.org/10.1016/j. bbalip.2006.03.023.
45. Careaga MM, Sprecher H. Synthesis of two hydroxy fatty acids from 7,10,13,16,19-docosapentaenoic acid by human platelets. J Biol Chem 1984;259:14413-7.
46. Benistant C, Achard F, Ben Slama S, et al. Docosapentaenoic acid (22:5, n-3): metabolism and effect on prostacyclin production in endothelial cells. Prostag Leukotr Essent Fatty Acids 1996;55:287-92. http://dx.doi.org/10.1016/S0952-3278(96)90010-1.
47. Kelly L, Grehan B, Chiesa AD, et al. The polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the aged rat. Neurobiol Aging 2011;32:2318.e1-2318.e15. http://dx.doi/10.1016/j.neurobiolaging.2010.04.001.
48. Tsuji M, Murota SI, Morita I. Docosapentaenoic acid (22:5, n-3) suppressed tube-forming activity in endothelial cells induced by vascular endothelial growth factor. Prostag Leukotr Essent Fatty Acids 2003;68:337-42. http://dx.doi.org/10.1016/S0952-3278(03)00025-5.
49. Solakivi T, Jaakkola O, Kalela A, et al. Lipoprotein docosapentaenoic acid is associated with serum matrix metalloproteinase-9 concentration. Lipids Health Dis 2005;4:8. http://dx.doi.org/10.1186/1476-511X-4-8.
50. Andriole GL, Humphrey PA, Serfling RJ, et al. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? J Natl Cancer Inst 2007;99:1355-6. http://dx.doi.org/10.1093/jnci/djm151.
51. Legler JM, Feuer EJ, Potosky AL, et al. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 1998;9:519-27. http://dx.doi.org/10.1023/A:1008805718310.
52. Giovannucci E. Commentary: serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial. Cancer Causes Control 2011;22:1055-9. http://dx.doi.org/10.1007/s10552-011-9776-x
53. Brouwer A, Longnecker MP, Birnbaum LS, et al. Characterization of potential endocrine-related health effects at low-dose levels of exposure to PCBS. Environ Health Perspect 1999;107(Suppl 4):639-49.
54. Ritchie JM, Vial SL, Fuortes LJ, et al. Comparison of proposed frameworks for grouping polychlorinated biphenyl congener data applied to a case-control pilot study of prostate cancer. Environ Res 2005;98:104-13. http://dx.doi.org/10.1016/j.envres.2004.05.013.
55. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate ancer. Prostate Cancer Prostatic Dis 2006;9:230-4. http://dx.doi.org/10.1038/sj.pcan.4500879.
56. Federico A, Morgillo F, Tuccillo C, et al. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007;121: 2381-6. http://dx.doi.org/10.1002/ijc.23192.
57. Lemaitre RN, Tanaka T, Tang W, et al. Genetic Loci Associated with Plasma Phospholipid n-3 Fatty Acids: A Meta-Analysis of Genome-Wide Association Studies from the CHARGE Consortium. PLoS Genet 2011;7:e1002193. http://dx.doi.org/10.1371/journal.pgen.1002193